Bifonazole
 | |
| Clinical data | |
|---|---|
| Trade names | Canespor, many others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| Chirality | Racemic mixture |
| |
| |
  (what is this?) (verify) | |
Bifonazole (trade name Canespor among othersantifungal drug used in form of ointments.
It was patented in 1974 and approved for medical use in 1983.carbamide for the treatment of onychomycosis.
Adverse effects
The most common side effect is a burning sensation at the application site. Other reactions, such as itching,
eczema or skin dryness, are rare.[3]
Bifonazole is a potent aromatase inhibitor in vitro.[4][5]
Pharmacology
Mechanism of action
Bifonazole has a dual mode of action. It inhibits fungal ergosterol biosynthesis at two points, via transformation of 24-methylendihydrolanosterol to desmethylsterol, together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs.[3][6]
Pharmacokinetics
Six hours after application, bifonazole concentrations range from 1000
papillary dermis.[3]
References
- ^ International Drug Names: Bifonazole.
- ISBN 9783527607495.
- ^ a b c Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Canesten Bifonazol-Creme.
- PMID 16330141.
- PMID 25243857.
- PMID 6372801.
Further reading
- Lackner TE, Clissold SP (August 1989). "Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses". Drugs. 38 (2): 204–225. S2CID 195697559.